Skip to main content
Top
Published in: Clinical Research in Cardiology 3/2015

01-03-2015 | Review

Pulmonary hypertension 2015: current definitions, terminology, and novel treatment options

Author: Stephan Rosenkranz

Published in: Clinical Research in Cardiology | Issue 3/2015

Login to get access

Abstract

Pulmonary hypertension (PH) is a common phenomenon that may occur as a consequence of various diseases (e.g., heart failure, chronic lung diseases, and pulmonary embolism), as a distinct disease of the small pulmonary arterioles, or a combination of both. Independently from the origin, PH has important impact on patient´s symptoms and life expectancy. The establishment of an exact diagnosis and classification, as well as the understanding of the hemodynamic interrelations, provides the basis for often challenging treatment decisions. Recently, the 5th World Symposium on PH took place in Nice, France, where important standards and definitions were specified. Furthermore, the results of recent phase III trials have led to the approval of new targeted therapies. The most relevant developments including the rating of novel treatment options are summarized in this article.
Literature
1.
go back to reference Galiè N, Hoeper MM, Humbert M et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung transplantation (ISHLT). Eur Heart J 30:2493–2537CrossRefPubMed Galiè N, Hoeper MM, Humbert M et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung transplantation (ISHLT). Eur Heart J 30:2493–2537CrossRefPubMed
2.
go back to reference Simonneau G, Gatzoulis MA, Adatia I et al (2013) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62(Suppl D):D34–D41CrossRefPubMed Simonneau G, Gatzoulis MA, Adatia I et al (2013) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62(Suppl D):D34–D41CrossRefPubMed
3.
go back to reference Simonneau G, Robbins IM, Beghetti M et al (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54(Suppl S):S43–S54CrossRefPubMed Simonneau G, Robbins IM, Beghetti M et al (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54(Suppl S):S43–S54CrossRefPubMed
4.
go back to reference Tuder RM, Archer SL, Dorfmüller P et al (2013) Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol 62(Suppl D):D4–D12CrossRefPubMedCentralPubMed Tuder RM, Archer SL, Dorfmüller P et al (2013) Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol 62(Suppl D):D4–D12CrossRefPubMedCentralPubMed
5.
go back to reference Soubrier F, Chung WK, Machado R et al (2013) Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 63(Suppl D):D13–D21CrossRef Soubrier F, Chung WK, Machado R et al (2013) Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 63(Suppl D):D13–D21CrossRef
6.
go back to reference McGoon M, Benza RL, Escribano-Subias P et al (2013) Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 62(Suppl D):D51–D59CrossRefPubMed McGoon M, Benza RL, Escribano-Subias P et al (2013) Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 62(Suppl D):D51–D59CrossRefPubMed
7.
go back to reference Rich S, Dantzker DR, Ayres SM et al (1987) Primary pulmonary hypertension: a national prospective study. Ann Intern Med 107:216–223CrossRefPubMed Rich S, Dantzker DR, Ayres SM et al (1987) Primary pulmonary hypertension: a national prospective study. Ann Intern Med 107:216–223CrossRefPubMed
8.
go back to reference D’Alonzo GE, Barst RJ, Ayres SM et al (1991) Survival in patients with primary pulmonary hypertension. Ann Intern Med 115:343–349CrossRefPubMed D’Alonzo GE, Barst RJ, Ayres SM et al (1991) Survival in patients with primary pulmonary hypertension. Ann Intern Med 115:343–349CrossRefPubMed
9.
go back to reference Humbert M, Sitbon O, Chaouat A et al (2010) Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 122:156–163CrossRefPubMed Humbert M, Sitbon O, Chaouat A et al (2010) Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 122:156–163CrossRefPubMed
10.
go back to reference Hoeper MM, Huscher D, Ghofrani HA et al (2013) Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol 168:871–880CrossRefPubMed Hoeper MM, Huscher D, Ghofrani HA et al (2013) Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol 168:871–880CrossRefPubMed
11.
go back to reference Ryan JJ, Rich JD, Thiruvoipati T et al (2012) Current practice for determining pulmonary capillary wedge pressure predisposes to serious errors in the classification of patients with pulmonary hypertension. Am Heart J 163:589–594CrossRefPubMed Ryan JJ, Rich JD, Thiruvoipati T et al (2012) Current practice for determining pulmonary capillary wedge pressure predisposes to serious errors in the classification of patients with pulmonary hypertension. Am Heart J 163:589–594CrossRefPubMed
12.
go back to reference LeVarge BL, Pomerantsev E, Channick RN (2014) Reliance on end-expiratory wedge pressure leads to misclassification of pulmonary hypertension. Eur Respir J 43:425 (Epub ahead of print)CrossRef LeVarge BL, Pomerantsev E, Channick RN (2014) Reliance on end-expiratory wedge pressure leads to misclassification of pulmonary hypertension. Eur Respir J 43:425 (Epub ahead of print)CrossRef
13.
go back to reference Hoeper M, Bogaard HJ, Condliffe R et al (2013) Definition and diagnosis of pulmonary hypertension. J Am Coll Cardiol 62(Suppl D):D42–D50CrossRefPubMed Hoeper M, Bogaard HJ, Condliffe R et al (2013) Definition and diagnosis of pulmonary hypertension. J Am Coll Cardiol 62(Suppl D):D42–D50CrossRefPubMed
14.
go back to reference Rosenkranz S, Behr J, Ewert R, Ghofrani HA et al (2011) Rechtherzkatheter-Untersuchung bei pulmonaler Hypertonie. Dtsch Med Wochenschr 136:2601–2620CrossRefPubMed Rosenkranz S, Behr J, Ewert R, Ghofrani HA et al (2011) Rechtherzkatheter-Untersuchung bei pulmonaler Hypertonie. Dtsch Med Wochenschr 136:2601–2620CrossRefPubMed
15.
go back to reference Kovacs G, Avian A, Olschewski A, Olschewski H (2013) Zero reference level for right heart catheterization. Eur Respir J 42:1586–1594CrossRefPubMed Kovacs G, Avian A, Olschewski A, Olschewski H (2013) Zero reference level for right heart catheterization. Eur Respir J 42:1586–1594CrossRefPubMed
16.
go back to reference Barst RJ, Gibbs SR, Ghofrani HA et al (2009) Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 54(Suppl S):S78–S84CrossRefPubMedCentralPubMed Barst RJ, Gibbs SR, Ghofrani HA et al (2009) Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 54(Suppl S):S78–S84CrossRefPubMedCentralPubMed
17.
go back to reference Galiè N, Corris PA, Frost A et al (2013) Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 62(Suppl D):D60–D72CrossRefPubMed Galiè N, Corris PA, Frost A et al (2013) Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 62(Suppl D):D60–D72CrossRefPubMed
18.
go back to reference Bolli MH, Boss C, Binkert C et al (2012) The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N′-propyl-sulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist. J Med Chem 55:7849–7861CrossRefPubMed Bolli MH, Boss C, Binkert C et al (2012) The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N′-propyl-sulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist. J Med Chem 55:7849–7861CrossRefPubMed
19.
go back to reference Gatfield J, Mueller Grandjean C, Sasse T, Clozel M, Nayler O (2012) Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS One 7:e47662CrossRefPubMedCentralPubMed Gatfield J, Mueller Grandjean C, Sasse T, Clozel M, Nayler O (2012) Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS One 7:e47662CrossRefPubMedCentralPubMed
20.
go back to reference Iglarz M, Binkert C, Morrison K et al (2008) Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 327:736–745CrossRefPubMed Iglarz M, Binkert C, Morrison K et al (2008) Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 327:736–745CrossRefPubMed
21.
go back to reference Pulido T, Adzerikho I, Channick RN, For the SERAPHIN Investigators et al (2013) Macitentan and morbidity and mortality in pulmonary arterial hypertension. New Engl J Med 369:809–818CrossRefPubMed Pulido T, Adzerikho I, Channick RN, For the SERAPHIN Investigators et al (2013) Macitentan and morbidity and mortality in pulmonary arterial hypertension. New Engl J Med 369:809–818CrossRefPubMed
22.
go back to reference Evgenov OV, Pacher P, Schmidt PM et al (2006) NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 5:755–768CrossRefPubMedCentralPubMed Evgenov OV, Pacher P, Schmidt PM et al (2006) NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 5:755–768CrossRefPubMedCentralPubMed
23.
go back to reference Ghofrani HA, Hoeper M, Halank M et al (2010) Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension. A phase II study. Eur Respir J 36:792–799CrossRefPubMed Ghofrani HA, Hoeper M, Halank M et al (2010) Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension. A phase II study. Eur Respir J 36:792–799CrossRefPubMed
24.
go back to reference Ghofrani HA, Galiè N, Grimminger F, For the PATENT Investigators et al (2013) Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369:330–340CrossRefPubMed Ghofrani HA, Galiè N, Grimminger F, For the PATENT Investigators et al (2013) Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369:330–340CrossRefPubMed
25.
go back to reference Ghofrani HA, D`Armini AM, Grimminger F, For the CHEST Investigators et al (2013) Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 369:319–329CrossRefPubMed Ghofrani HA, D`Armini AM, Grimminger F, For the CHEST Investigators et al (2013) Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 369:319–329CrossRefPubMed
26.
go back to reference Simonneau G, Lang I, Torbicki A, Hoeper MM, Delcrox M, Karlocai K, Galiè N (2012) Selexipag, an oral, selective IP receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 40:874–880CrossRefPubMed Simonneau G, Lang I, Torbicki A, Hoeper MM, Delcrox M, Karlocai K, Galiè N (2012) Selexipag, an oral, selective IP receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 40:874–880CrossRefPubMed
27.
go back to reference Actelion press release: selexipag meets primary endpoint in pivotal phase III GRIPHON outcome study in patients with pulmonary arterial hypertension (2014) (Published June 16) Actelion press release: selexipag meets primary endpoint in pivotal phase III GRIPHON outcome study in patients with pulmonary arterial hypertension (2014) (Published June 16)
28.
go back to reference Freyhaus T, Dumitrescu D, Berghausen E, Vantler M, Caglayan E, Rosenkranz S (2012) Imatinib mesylate for pulmonary arterial hypertension. Exp Opin Investig Drugs 21:119–134CrossRef Freyhaus T, Dumitrescu D, Berghausen E, Vantler M, Caglayan E, Rosenkranz S (2012) Imatinib mesylate for pulmonary arterial hypertension. Exp Opin Investig Drugs 21:119–134CrossRef
29.
go back to reference Hoeper MM, Barst RJ, Bourge RC et al (2013) Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 127:1128–1138CrossRefPubMed Hoeper MM, Barst RJ, Bourge RC et al (2013) Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 127:1128–1138CrossRefPubMed
30.
go back to reference GlaxoSmithKline/Gilead press release: first-line combination of ambrisentan and tadalafil reduces risk of clinical failure compared to monotherapy in pulmonary arterial hypertension outcomes study (2014) (Published September 8) GlaxoSmithKline/Gilead press release: first-line combination of ambrisentan and tadalafil reduces risk of clinical failure compared to monotherapy in pulmonary arterial hypertension outcomes study (2014) (Published September 8)
31.
go back to reference Galiè N, for the AMBITION Investigators (2014) The AMBITION study: design and results. Presented at ERS International Congress 2014 (abstract #2916) Galiè N, for the AMBITION Investigators (2014) The AMBITION study: design and results. Presented at ERS International Congress 2014 (abstract #2916)
32.
go back to reference Sitbon O, Jais X, Savale L et al (2014) Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J 43:1691–1697CrossRefPubMed Sitbon O, Jais X, Savale L et al (2014) Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J 43:1691–1697CrossRefPubMed
33.
go back to reference Olsson KM, Delcroix M, Ghofrani HA et al (2014) Anticoagulation and survival in pulmonary arterial hypertension: results from the COMPERA registry. Circulation 129:57–65CrossRefPubMed Olsson KM, Delcroix M, Ghofrani HA et al (2014) Anticoagulation and survival in pulmonary arterial hypertension: results from the COMPERA registry. Circulation 129:57–65CrossRefPubMed
34.
go back to reference Rhodes CJ, Howard LS, Busbridge M et al (2011) Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes and mechanistic insights. J Am Coll Cardiol 58:300–309CrossRefPubMed Rhodes CJ, Howard LS, Busbridge M et al (2011) Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes and mechanistic insights. J Am Coll Cardiol 58:300–309CrossRefPubMed
35.
go back to reference Ruiter G, Lanser IJ, de Man FS et al (2014) Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension. Rheumatology 53:285–292CrossRefPubMed Ruiter G, Lanser IJ, de Man FS et al (2014) Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension. Rheumatology 53:285–292CrossRefPubMed
36.
go back to reference Viethen T, Gerhardt F, Dumitrescu D, Knoop-Busch S, ten Freyhaus H, Rudolph TK, Baldus S, Rosenkranz S (2014) Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study. Int J Cardiol. doi:10.1016/j.ijcard.2014.04.233 (Epub ahead of print)PubMed Viethen T, Gerhardt F, Dumitrescu D, Knoop-Busch S, ten Freyhaus H, Rudolph TK, Baldus S, Rosenkranz S (2014) Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study. Int J Cardiol. doi:10.​1016/​j.​ijcard.​2014.​04.​233 (Epub ahead of print)PubMed
37.
go back to reference Bursi F, McNallan SM, Redfield MM et al (2012) Pulmonary pressures and death in heart failure. J Am Coll Cardiol 59:222–231CrossRefPubMed Bursi F, McNallan SM, Redfield MM et al (2012) Pulmonary pressures and death in heart failure. J Am Coll Cardiol 59:222–231CrossRefPubMed
38.
go back to reference Lam CS, Roger VL, Rodeheffer RJ et al (2009) Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 53:1119–1126CrossRefPubMedCentralPubMed Lam CS, Roger VL, Rodeheffer RJ et al (2009) Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 53:1119–1126CrossRefPubMedCentralPubMed
39.
go back to reference Ghio S, Gavazzi A, Campana C et al (2001) Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 37:183–188CrossRefPubMed Ghio S, Gavazzi A, Campana C et al (2001) Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 37:183–188CrossRefPubMed
40.
go back to reference Melenovsky V, Hwang SJ, Lin G, Redfield MM, Borlaug BA (2014) Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J [Epub ahead of print] Melenovsky V, Hwang SJ, Lin G, Redfield MM, Borlaug BA (2014) Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J [Epub ahead of print]
41.
go back to reference Miller WL, Grill DE, Borlaug BA (2013) Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction. JACC Heart Fail 1:290–299CrossRefPubMed Miller WL, Grill DE, Borlaug BA (2013) Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction. JACC Heart Fail 1:290–299CrossRefPubMed
42.
go back to reference Seiffert M, Sinning JM, Meyer A et al (2014) Development of a risk score for outcome after transcatheter aortic valve implantation. Clin Res Cardiol 103:631–640CrossRefPubMed Seiffert M, Sinning JM, Meyer A et al (2014) Development of a risk score for outcome after transcatheter aortic valve implantation. Clin Res Cardiol 103:631–640CrossRefPubMed
43.
go back to reference Zuern CS, Eick C, Rizas K et al (2012) Prognostic value of mild-to-moderate pulmonary hypertension in patients with severe aortic valve stenosis undergoing aortic valve replacement. Clin Res Cardiol 101:81–88CrossRefPubMed Zuern CS, Eick C, Rizas K et al (2012) Prognostic value of mild-to-moderate pulmonary hypertension in patients with severe aortic valve stenosis undergoing aortic valve replacement. Clin Res Cardiol 101:81–88CrossRefPubMed
44.
go back to reference Abraham WT, Adamson PB, Bourge RC et al (2011) Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 377:658–666CrossRefPubMed Abraham WT, Adamson PB, Bourge RC et al (2011) Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 377:658–666CrossRefPubMed
45.
go back to reference Naejie R, Vachiéry JL, Vanderpool R (2013) The transpulmonary pressure gradient for the diagnoisis of pulmonary vascular disease. Eur Respir J 41:217–223CrossRef Naejie R, Vachiéry JL, Vanderpool R (2013) The transpulmonary pressure gradient for the diagnoisis of pulmonary vascular disease. Eur Respir J 41:217–223CrossRef
46.
go back to reference Gerges C, Gerges M, Lang MB et al (2013) Diastolic pulmonary vascular pressure gradient. A predictor of prognosis in out-of-proportion pulmonary hypertension. Chest 143:758–766CrossRefPubMed Gerges C, Gerges M, Lang MB et al (2013) Diastolic pulmonary vascular pressure gradient. A predictor of prognosis in out-of-proportion pulmonary hypertension. Chest 143:758–766CrossRefPubMed
47.
go back to reference Rosenkranz S, Bondermann D, Buerke M et al (2011) Pulmonary hypertension due to left heart disease: updated recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 154(Suppl):S34–S44CrossRefPubMed Rosenkranz S, Bondermann D, Buerke M et al (2011) Pulmonary hypertension due to left heart disease: updated recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 154(Suppl):S34–S44CrossRefPubMed
48.
go back to reference Vachiery JL, Adir Y, Barbera JA et al (2013) Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol 62(Suppl D):D100–D108CrossRefPubMed Vachiery JL, Adir Y, Barbera JA et al (2013) Pulmonary hypertension due to left heart diseases. J Am Coll Cardiol 62(Suppl D):D100–D108CrossRefPubMed
49.
go back to reference Guazzi M, Vicenzi M, Arena R, Guazzi MD (2011) Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 124:164–174CrossRefPubMed Guazzi M, Vicenzi M, Arena R, Guazzi MD (2011) Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 124:164–174CrossRefPubMed
50.
go back to reference Dumitrescu D, Seck C, Möhle L, Erdmann E, Rosenkranz S (2012) Therapeutic potential of sildenafil in patients with heart failure and reactive pulmonary hypertension—results of compassionate care treatment. Int J Cardiol 154:205–206CrossRefPubMed Dumitrescu D, Seck C, Möhle L, Erdmann E, Rosenkranz S (2012) Therapeutic potential of sildenafil in patients with heart failure and reactive pulmonary hypertension—results of compassionate care treatment. Int J Cardiol 154:205–206CrossRefPubMed
51.
go back to reference Redfield MM, Chen HH, Borlaug BA et al (2013) Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 309:1268–1277CrossRefPubMed Redfield MM, Chen HH, Borlaug BA et al (2013) Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 309:1268–1277CrossRefPubMed
52.
go back to reference Bonderman D, Ghio S, Felix SB, For the LEPHT Investigators et al (2013) Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 128:502–511CrossRefPubMed Bonderman D, Ghio S, Felix SB, For the LEPHT Investigators et al (2013) Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 128:502–511CrossRefPubMed
53.
go back to reference Hoeper MM, Andreas S, Bastian A et al (2011) Pulmonary hypertension due to chronic lung disease. Updated recommendations of the cologne consensus conference 2011. Int J Cardiol 154(Suppl):S45–S53CrossRefPubMed Hoeper MM, Andreas S, Bastian A et al (2011) Pulmonary hypertension due to chronic lung disease. Updated recommendations of the cologne consensus conference 2011. Int J Cardiol 154(Suppl):S45–S53CrossRefPubMed
54.
go back to reference Boerrigter BG, Bogaard HJ, Trip P et al (2012) Ventilatory and cardiocirculatory exercise profiles in COPD: the role of pulmonary hypertension. Chest 142:1166–1174CrossRefPubMed Boerrigter BG, Bogaard HJ, Trip P et al (2012) Ventilatory and cardiocirculatory exercise profiles in COPD: the role of pulmonary hypertension. Chest 142:1166–1174CrossRefPubMed
55.
go back to reference Seeger W, Adir Y, Barbera JA et al (2013) Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 62(Suppl D):D109–D116CrossRefPubMed Seeger W, Adir Y, Barbera JA et al (2013) Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 62(Suppl D):D109–D116CrossRefPubMed
56.
go back to reference Mayer E, Jenkins D, Lindner J et al (2011) Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg 141:702–710CrossRefPubMed Mayer E, Jenkins D, Lindner J et al (2011) Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg 141:702–710CrossRefPubMed
57.
go back to reference Kim NH, Delcroix M, Jenkins DP et al (2013) Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol 62(Suppl D):D92–D99CrossRefPubMed Kim NH, Delcroix M, Jenkins DP et al (2013) Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol 62(Suppl D):D92–D99CrossRefPubMed
58.
go back to reference Madani MM, Auger WR, Pretorius V et al (2012) Pulmonary endarterectomy: recent changes in a single institution´s experience of more than 2,700 patients. Ann Thorac Surg 94:97–103CrossRefPubMed Madani MM, Auger WR, Pretorius V et al (2012) Pulmonary endarterectomy: recent changes in a single institution´s experience of more than 2,700 patients. Ann Thorac Surg 94:97–103CrossRefPubMed
59.
go back to reference Sugimura K, Fukumoto Y, Satoh K et al (2012) Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension. Circ J 76:485–488CrossRefPubMed Sugimura K, Fukumoto Y, Satoh K et al (2012) Percutaneous transluminal pulmonary angioplasty markedly improves pulmonary hemodynamics and long-term prognosis in patients with chronic thromboembolic pulmonary hypertension. Circ J 76:485–488CrossRefPubMed
Metadata
Title
Pulmonary hypertension 2015: current definitions, terminology, and novel treatment options
Author
Stephan Rosenkranz
Publication date
01-03-2015
Publisher
Springer Berlin Heidelberg
Published in
Clinical Research in Cardiology / Issue 3/2015
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-014-0765-4

Other articles of this Issue 3/2015

Clinical Research in Cardiology 3/2015 Go to the issue